Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 4/20 | 0.48 |
| ▸ | ESRRB | O95718 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695538 | 0.82 | ATM (0.54) | MAPK1ATMADORA2AKMT2AMEN1 | |
| SCHEMBL26795951 | 0.73 | ALDH1A1 (0.50) | ESRRGESRRBCFTRKMT2AMEN1 | |
| SCHEMBL11690472 | 0.72 | CFTR (0.55) | ESRRGESRRBCFTRALDH1A1KDM4E | |
| SCHEMBL105277 | 0.71 | ALDH1A1 (0.68) | ESRRGESRRBCFTRKMT2AMEN1 | |
| SCHEMBL31273443 | 0.71 | ALDH1A1 (0.68) | ESRRGESRRBCFTRKMT2AMEN1 | |
| SCHEMBL16418929 | 0.70 | CFTR (0.73) | ESRRGESRRBATMCFTRKMT2A | |
| SCHEMBL27855171 | 0.70 | ALDH1A1 (0.50) | ESRRGESRRBCFTRKMT2AMEN1 | |
| SCHEMBL6810401 | 0.69 | ATM (0.63) | MAPK1ATMEPHX1KMT2AMEN1 | |
| SCHEMBL6314167 | 0.69 | HPGD (0.47) | MAPK1ATMADORA2AEPHX1KMT2A | |
| SCHEMBL1722083 | 0.68 | ALDH1A1 (0.55) | ESRRGESRRBATMCFTRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102292329-B | Inhibitors of bruton's tyrosine kinase | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | disclosed |
| EP-2421854-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8318719-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2421854-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| CN-102292329-A | Inhibitors of bruton's tyrosine kinase | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2010122038-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273768-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | ESRRG 3317/4885ESRRB 4715/4885MAPK1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.